Protagonist Therapeutics, INC Form 4 insider transactions

Dinesh V Ph D Patel, President and CEO and a Director of Protagonist Therapeutics, Inc, sold 100,000 shares of common stock on August 10, 2026.

Protagonist Therapeutics Director William D. Waddill reported transactions involving the sale of common stock and the exercise of stock options, executed under a pre-arranged 10b5-1 trading plan.

Protagonist Therapeutics director William D. Waddill exercised stock options and sold 9,000 shares under a 10b5-1 trading plan.

Director William D. Waddill exercised options and sold 9,000 shares of Protagonist Therapeutics, Inc. under a 10b5-1 plan.

CEO Dinesh V. Patel exercised 75,000 stock options and sold the resulting shares under a pre-established 10b5-1 trading plan.

Protagonist Therapeutics CEO Dinesh V. Patel exercised 75,000 stock options and sold the resulting shares on May 12, 2026.

Director Bryan Giraudo exercised options for 36,000 shares of Protagonist Therapeutics and subsequently sold them.

CEO Dinesh V. Patel gifted 1,460 shares of Protagonist Therapeutics common stock to family and friends.

CFO Asif Ali sold 1,750 shares of Protagonist Therapeutics to cover tax obligations related to restricted stock unit vesting.

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, exercised options and sold 15,000 shares of common stock.

Protagonist Therapeutics Director Harold E. Selick exercised options and sold 24,000 shares of common stock under a pre-arranged 10b5-1 plan.

Protagonist Therapeutics CFO Asif Ali exercised stock options and subsequently sold a portion of his common stock holdings for a significant profit.

Protagonist Therapeutics President and CEO Dinesh V. Patel reported gifting 50,000 common shares and exercising and selling 54,700 shares of common stock.

Protagonist Therapeutics Director William D. Waddill exercised stock options and sold 20,000 common shares for a significant gain in a pre-planned transaction.

Protagonist Therapeutics CEO Dinesh V. Patel reported exercising stock options and selling common stock, alongside a charitable donation, under a pre-arranged trading plan.

Protagonist Therapeutics' CFO Asif Ali reported exercising stock options and subsequently selling a significant number of common shares under a 10b5-1 plan.

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, reported the sale of 23,151 common shares and the exercise of 10,000 stock options under a pre-arranged 10b5-1 plan.

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, sold 9,514 shares of common stock at $82.48 per share to cover tax withholding obligations.

Protagonist Therapeutics' President and CEO, Dinesh V. Patel, sold 34,438 shares of common stock at $82.48 per share to cover tax withholding obligations.

Protagonist Therapeutics CFO Asif Ali sold 8,588 shares of common stock at $82.48 per share to cover tax withholding obligations.

Protagonist Therapeutics Director Harold E. Selick exercised stock options, acquiring 14,299 shares of common stock.

Protagonist Therapeutics director Harold E. Selick received a grant of restricted stock units and stock options, increasing his beneficial ownership.

Protagonist Therapeutics director William D. Waddill was granted 2,695 restricted stock units and options for 3,762 shares of common stock.

Protagonist Therapeutics Director Bryan Giraudo received grants of restricted stock units and stock options, increasing his beneficial ownership.

Protagonist Therapeutics director Lewis T. Williams received a grant of 2,695 restricted stock units and options for 3,762 shares on January 2, 2026.

Protagonist Therapeutics Director Sarah A. O'Dowd acquired 2,695 restricted stock units and 3,762 stock options on January 2, 2026.

Protagonist Therapeutics CEO Dinesh V. Patel received grants of 95,400 restricted stock units and 120,200 stock options on January 2, 2026.

Protagonist Therapeutics' CFO, Asif Ali, was granted 25,600 restricted stock units and options for 32,000 shares of common stock.

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, was granted 25,600 restricted stock units and 32,000 stock options.

Protagonist Therapeutics CEO Dinesh V. Patel gifted 440 shares of common stock to his grandchild on November 21, 2025.